F. No. 6/59/2026-DGTR
Government of India
Department of Commerce
Ministry of Commerce & Industry
(Directorate General of Trade Remedies)
*****

4th Floor, Jeevan Tara Building
5, Parliament Street, New Delhi – 110001
Date: 30th October, 2026

To,

All interested parties

Subject: PUC and PCN methodology in the anti-dumping investigation concerning imports of "Amoxycillin Trihydrate originating in or exported from China PR".

This has reference to the initiation notification F. No. 6/59/2026-DGTR dated 24th September 2026 issued in Case No. AD(OI)/060/2026, whereby an anti-dumping investigation concerning imports of "**Amoxycillin Trihydrate**" originating in exported from China PR was initiated on the application filed by Apitoria Pharma Private Limited. The scope of the product under consideration was notified at paragraphs 4 and 5 of the said notification.

2. Subsequently, the non-confidential version of the application filed by the domestic industry was shared with concerned interested parties vide Letter/Email dated 25th September 2026 and the interested parties were granted an opportunity to present their comments on the scope of the product under consideration (PUC), and product control number (PCN) methodology, within a period of 15 days from the date of intimation, which ended on 10th October 2026.

3. The product under consideration (hereinafter referred to as "PUC") was defined as under:

- *The product under consideration in the present application is "**Amoxycillin Trihydrate**". "Amoxicillin" is a semi synthetic antibiotic, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Amoxicillin is used to reduce the development of drug-resistant bacteria. Amoxicillin is a broad-spectrum penicillin antibiotic mainly used to treat bacterial infections of the respiratory tract (bronchitis, pneumonia, sinusitis), ear (otitis media), throat (strep throat), urinary tract, skin, and dental infections. It's also used, in combination with other drugs, to treat H. pylori-related peptic ulcers, and sometimes given preventively before certain dental or surgical procedures.*

4. No PCN methodology was proposed in the initiation notification.

5. No comments in regard to the scope of PUC and PCN methodology have been received from the interested parties and therefore the authority adopts the same scope of product under consideration

as notified in the initiation Notification No.6/59/2026-DGTR dated 24th September 2026 without any changes and no PCN methodology is adopted at this stage.

6. This communication is limited to clarifying the scope of the product under consideration for which the present investigation is being conducted. This does not preclude interested parties from providing relevant information and evidence to substantiate their requests for exclusion for any particular product. The Authority shall decide the scope of the product under consideration for any measures recommended, after considering relevant information and evidence furnished by all interested parties during the course of the investigation.

sd./-
(Y Jaya Priyadarshini)
Economic Adviser
Email: dir13-dgtr@gov.in